New Jersey lawmakers are exploring ways to lower prescription drug costs and out-of-pocket patient costs – but a new proposal is not the answer! New Jersey legislation, A-1747/S-329 would create a government-appointed Prescription Drug Affordability Board that has the authority to determine drug costs and value without taking Patient preferences into account.

New Jersey A-1747/S-329 would threaten Patients, health equity, and the very innovations that so many Patients here and beyond our state borders rely on WITHOUT actually lowering out-of-pocket costs for Patients. Send a letter to your New Jersey legislator now: Tell them to oppose A-1747/S-329.

Find out if your state legislator is a member of the Assembly Financial Institutions and Insurance Committee hearing the bill and join BioNJ in sending a letter to defend Patient access to innovative treatments and care.